Abstract
Numerous preclinical studies have been carried out using mesenchymal stem cells (MSCs) therapy for ischemic stroke. The purpose of the present meta-analysis is to review the quality of preclinical studies. In all, 4,361 articles were identified, out of which 64 studies were included (excluding in vitro studies). The results were obtained across species, route, and time of administration, immunogenicity, and doses. The median quality score 4.90/10, confidence interval 95%, and large effect size were observed, which strongly supports the translation potential of MSC therapy for ischemic stroke.
| Original language | English (US) |
|---|---|
| Journal | Clinical Pharmacology and Therapeutics |
| DOIs | |
| State | Accepted/In press - Jan 1 2017 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
Cite this
Mesenchymal Stem Cell Therapy in Ischemic Stroke : A Meta-analysis of Preclinical Studies. / Sarmah, Deepaneeta; Agrawal, Vishal; Rane, Pallavi; Bhute, Shashikala; Watanabe, Mitsuyoshi; Kalia, Kiran; Ghosh, Zhumur; Dave, Kunjan R; Yavagal, Dileep R; Bhattacharya, Pallab.
In: Clinical Pharmacology and Therapeutics, 01.01.2017.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Mesenchymal Stem Cell Therapy in Ischemic Stroke
T2 - A Meta-analysis of Preclinical Studies
AU - Sarmah, Deepaneeta
AU - Agrawal, Vishal
AU - Rane, Pallavi
AU - Bhute, Shashikala
AU - Watanabe, Mitsuyoshi
AU - Kalia, Kiran
AU - Ghosh, Zhumur
AU - Dave, Kunjan R
AU - Yavagal, Dileep R
AU - Bhattacharya, Pallab
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Numerous preclinical studies have been carried out using mesenchymal stem cells (MSCs) therapy for ischemic stroke. The purpose of the present meta-analysis is to review the quality of preclinical studies. In all, 4,361 articles were identified, out of which 64 studies were included (excluding in vitro studies). The results were obtained across species, route, and time of administration, immunogenicity, and doses. The median quality score 4.90/10, confidence interval 95%, and large effect size were observed, which strongly supports the translation potential of MSC therapy for ischemic stroke.
AB - Numerous preclinical studies have been carried out using mesenchymal stem cells (MSCs) therapy for ischemic stroke. The purpose of the present meta-analysis is to review the quality of preclinical studies. In all, 4,361 articles were identified, out of which 64 studies were included (excluding in vitro studies). The results were obtained across species, route, and time of administration, immunogenicity, and doses. The median quality score 4.90/10, confidence interval 95%, and large effect size were observed, which strongly supports the translation potential of MSC therapy for ischemic stroke.
UR - http://www.scopus.com/inward/record.url?scp=85038015460&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85038015460&partnerID=8YFLogxK
U2 - 10.1002/cpt.927
DO - 10.1002/cpt.927
M3 - Article
C2 - 29090465
AN - SCOPUS:85038015460
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
SN - 0009-9236
ER -